CL2016003326A1 - Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t - Google Patents

Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t

Info

Publication number
CL2016003326A1
CL2016003326A1 CL2016003326A CL2016003326A CL2016003326A1 CL 2016003326 A1 CL2016003326 A1 CL 2016003326A1 CL 2016003326 A CL2016003326 A CL 2016003326A CL 2016003326 A CL2016003326 A CL 2016003326A CL 2016003326 A1 CL2016003326 A1 CL 2016003326A1
Authority
CL
Chile
Prior art keywords
heterocyclic compounds
ror
retinoid
gamma
inhibitors
Prior art date
Application number
CL2016003326A
Other languages
English (en)
Inventor
Satoshi Yamamoto
Junya Shirai
Tsuneo Oda
Mitsunori Kono
Atsuko Ochida
Takashi Imada
Hidekazu Tokuhara
Yoshihide Tomata
Naoki Ishii
Michiko Tawada
Yoshiyuki Fukase
Tomoya Yukawa
Shoji Fukumoto
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2016003326A1 publication Critical patent/CL2016003326A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

<p>Se proporciona compuestos heterocíclicos que tienen una acción inhibidora de RORyt representados por la fórmula (I):</p> <p>* (figura de estructura pagina 386 escrito 26-12-2016)</p> <p> </p> <p>en donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales.</p>
CL2016003326A 2014-07-01 2016-12-26 Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t CL2016003326A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014136359 2014-07-01
JP2014262775 2014-12-25

Publications (1)

Publication Number Publication Date
CL2016003326A1 true CL2016003326A1 (es) 2017-08-11

Family

ID=53724416

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003326A CL2016003326A1 (es) 2014-07-01 2016-12-26 Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t

Country Status (23)

Country Link
US (5) US9365520B2 (es)
EP (1) EP3164388A1 (es)
JP (1) JP6611363B2 (es)
KR (1) KR20170016987A (es)
CN (1) CN106795118B (es)
AU (1) AU2015285142B2 (es)
CA (1) CA2954042A1 (es)
CL (1) CL2016003326A1 (es)
CO (1) CO2017000332A2 (es)
CR (1) CR20170017A (es)
DO (1) DOP2016000337A (es)
EA (1) EA031262B1 (es)
GE (1) GEP20196942B (es)
IL (1) IL249698A0 (es)
MA (1) MA40060A (es)
MX (1) MX2016016870A (es)
PE (1) PE20170267A1 (es)
PH (1) PH12016502574A1 (es)
SG (1) SG11201610729XA (es)
TN (1) TN2016000567A1 (es)
TW (1) TW201609751A (es)
UY (1) UY36199A (es)
WO (1) WO2016002968A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018126A4 (en) * 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC COMPOUND
US9365520B2 (en) 2014-07-01 2016-06-14 Takeda Pharmaceutical Company Limited Heterocyclic compound
JPWO2016039408A1 (ja) 2014-09-11 2017-06-22 武田薬品工業株式会社 複素環化合物
CN105472125B (zh) * 2015-11-16 2019-11-26 联想(北京)有限公司 一种信息处理方法及电子设备
CR20180328A (es) 2015-12-15 2018-08-09 Astrazeneca Ab Compuestos de isoindol
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド
JPWO2019044940A1 (ja) * 2017-08-31 2020-08-13 東レ株式会社 環状アミン誘導体及びその医薬用途
RU2761436C1 (ru) 2017-11-17 2021-12-08 Целликс Био Прайвет Лимитед Композиции и способы лечения нарушений со стороны органа зрения
US20200392107A1 (en) * 2018-01-31 2020-12-17 Toray Industries, Inc. Cyclic amine derivative and medical use thereof
RU2686692C1 (ru) * 2018-06-29 2019-04-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) Применение N-(6,8,8-триметил-8,9-дигидрофуро[3,2-h]хинолин-5-ил)ацетамида в качестве средства для фототерапии псориаза и псориатического артрита
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
WO2021228217A1 (zh) * 2020-05-15 2021-11-18 上海辉启生物医药科技有限公司 可用作RORγ调节剂的苯胺类化合物
CN116348096A (zh) 2020-09-21 2023-06-27 欧克尼医疗有限公司 可在子宫腔内定位的装置及其治疗方法
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2759533B1 (en) 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
IN2014CN02805A (es) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2013100027A1 (ja) 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
US9403774B2 (en) * 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC COMPOUND
US10472376B2 (en) 2013-07-03 2019-11-12 Takeda Pharmaceutical Company Limited Amide compound
US9365520B2 (en) 2014-07-01 2016-06-14 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
SG11201610729XA (en) 2017-01-27
US20160176873A1 (en) 2016-06-23
CN106795118B (zh) 2019-10-08
US9650343B2 (en) 2017-05-16
US9365520B2 (en) 2016-06-14
JP2017527530A (ja) 2017-09-21
PH12016502574A1 (en) 2017-04-17
PE20170267A1 (es) 2017-04-12
US20170144973A1 (en) 2017-05-25
UY36199A (es) 2016-01-29
MA40060A (fr) 2016-01-07
JP6611363B2 (ja) 2019-11-27
CA2954042A1 (en) 2016-01-07
CO2017000332A2 (es) 2017-07-11
GEP20196942B (en) 2019-02-11
EP3164388A1 (en) 2017-05-10
MX2016016870A (es) 2017-05-01
US20160002169A1 (en) 2016-01-07
US9630924B2 (en) 2017-04-25
US20160176822A1 (en) 2016-06-23
EA201790112A1 (ru) 2017-05-31
EA031262B1 (ru) 2018-12-28
AU2015285142A1 (en) 2017-02-02
US9573903B2 (en) 2017-02-21
AU2015285142B2 (en) 2019-02-21
TN2016000567A1 (en) 2018-04-04
CR20170017A (es) 2017-05-16
US20160176872A1 (en) 2016-06-23
KR20170016987A (ko) 2017-02-14
CN106795118A (zh) 2017-05-31
US10093629B2 (en) 2018-10-09
DOP2016000337A (es) 2017-04-16
WO2016002968A1 (en) 2016-01-07
TW201609751A (zh) 2016-03-16
IL249698A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
CL2016003326A1 (es) Compuestos heterocíclicos y sus usos como inhibidores de receptor huérfano relacionado con retinoide (ror) gama-t
CL2016002573A1 (es) Compuesto de ciclopropanamina y sus usos.
BR112017005444A2 (pt) indazoles substituídos por benzil como inibidores bub1.
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
DK3229840T5 (da) 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
CL2017002689A1 (es) Derivados de pirrolidincarboxamido y métodos para prepararlos y usarlos
CO2019012125A2 (es) Inhibidores ip6k
CL2017001467A1 (es) Compuestos de dihidropirimidin - 2 - ona y sus usos médicos
DK3724165T3 (da) Nye benzamidderivater som PPAR-gamma-modulatorer
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
CL2017000105A1 (es) Novedosas pirimidinas 2,5-sustituidas.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CL2016002779A1 (es) Composición para el cuidado de la piel
DK3555048T3 (da) Nye picolinsyrederivater og deres anvendelse som mellemprodukter
BR112016000965A2 (pt) Compostos imidazotia(dia)zol sulfonamidas, composição, usos dos mesmos, métodos para o controle de um nematódeo parasítico e para a proteção de uma semente e semente
UY35650A (es) Compuesto heterocíclico
CL2020000586A1 (es) Moduladores de la expresión de enac.
DK3668965T3 (da) Biologisk methaniseringsreaktor
CL2016003230A1 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ECSP17006555A (es) Compuestos heterocíclicos y su uso como retinoides relacionados con el receptor huerfano (ror) del inhibidor de gam-ma-t
UY36222A (es) Sales de tungsteno (VI) para su uso en el tratamiento de la infertilidad, para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético, así como para mejorar la eficacia de las técnicas de reproducción asistida.